A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma.

ABSTRACT:

Background

Metastasis is a hallmark of cancer and responsible for most cancer deaths. Migrastatics were defined as drugs interfering with all modes of cancer cell invasion and thus cancers' ability to metastasise. First anti-metastatic treatments have recently been approved.

Methods

We used bioinformatic analyses of publicly available melanoma databases. Experimentally, we performed in vitro target validation (including 2.5D cell morphology analysis and mass spectrometric analysis of RhoA binding partners), developed a new traceable spontaneously metastasising murine melanoma model for in vivo validation, and employed histology (haematoxylin/eosin and phospho-myosin II staining) to confirm drug action in harvested tumour tissues.

Results

Unbiased and targeted bioinfor

SUBMITTER: Maiques O 

PROVIDER: S-EPMC8405734 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature